Comparative Pharmacology
Head-to-head clinical analysis: DIABETA versus GLUCOTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIABETA versus GLUCOTROL.
DIABETA vs GLUCOTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glyburide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor 1 (SUR1) on ATP-sensitive potassium channels, causing depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Initial: 2.5-5 mg orally once daily, titrating to max 20 mg/day in 1-2 divided doses. Maintenance: 5-10 mg/day.
Initial dose 5 mg orally once daily, increased by 2.5-5 mg increments weekly based on glycemic response; maximum 20 mg daily as single or divided doses (for doses >15 mg, administer in divided doses).
None Documented
None Documented
Terminal elimination half-life is approximately 10–12 hours in healthy individuals. Clinically, this supports once-daily dosing; may be prolonged in renal impairment.
Terminal elimination half-life: 2-4 hours (mean 3.4 hours) in normal subjects; extended up to 8-12 hours in elderly or hepatic impairment due to reduced clearance.
Approximately 50% renal (unchanged drug and metabolites), 50% biliary/fecal. Renal elimination accounts for 50% of dose, with about 20% unchanged and 30% as metabolites. Biliary excretion of metabolites contributes to fecal elimination.
Primarily renal: ~80% as metabolites (mainly 4-trans-hydroxyglipizide and 3-cis-hydroxyglipizide) and ~10% unchanged; fecal: ~10%.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic